Melissa Leichter Announces The Newly FDA Approved Subcutaneous Prophylactic Treatment for Hemophilia A or B
Melissa Leichter, Rare Disease Executive, Novo Nordisk, shared a proud announcement post on LinkedIn:
”Today marks an exciting step forward for the hemophilia community. The FDA has approved our new subcutaneous prophylactic treatment for patients aged 12 and older living with hemophilia A or B.
This approval builds on our earlier indication for people living with hemophilia with inhibitors and reflects our continued commitment to expanding access and reimagining care across the hemophilia landscape.
Behind this milestone is a team of passionate, driven individuals who work tirelessly to bring innovative solutions to life. I am incredibly proud to be part of this journey—one that’s focused on delivering better options and more control for people navigating life with hemophilia. Thank you to the entire team who has contributed to this great achievement. Your dedication makes a real difference.”
Melissa Leichter proudly shares news on FDA Approvement for Alhemo.
Latest news in the field of Hemophilia Management featured in Hemostasis Today.
-
Aug 8, 2026, 05:23Mohsin Naseer։ From Beginner to Published Researcher
-
Aug 8, 2026, 04:50Marc Carrier: Celebrating 20 Years with ASH CRTI
-
Aug 8, 2026, 04:37Megan Adediran: Building Confidence for a Life Beyond Haemophilia
-
Aug 8, 2026, 04:32Megan Kavanaugh Roussos: Airborne Medical Expands Portfolio with WoundClot Advanced Hemostatic Technology
-
Aug 8, 2026, 04:25Maymoon Madkhali։ First Report of a Rare D– – Blood Phenotype in Saudi Arabia
-
Aug 8, 2026, 04:13Alexandra Bernal: Uncovering the Anticoagulant Role of Factor V in Hemophilia A
-
Aug 8, 2026, 04:03Wellington Fernandes: Honored to Join the Faculty of Medicine of USP as Professor of Hematology
-
Aug 8, 2026, 04:01Noa Ezra: How Senescent Cardiac Cells Drive a Pro-Thrombotic State
-
Aug 8, 2026, 03:56Omid Khalafi: PCT – The Platelet Parameter Almost Everyone Ignores